Ed Silverman

The number of people using injectable obesity treatments is increasing rapidly, and it is leading to declines in obesity, according to a new survey

Cigna Group will eliminate prescription drug rebates in many of its commercial health plans in 2027, a practice that has drawn the ire of President Trump

The Congressional Budget Office says exemptions for orphan drugs as part of Medicare price negotiations will cost taxpayers an additional $3.9 billion.

The FDA announced the first nine recipients of the Commissioner’s National Priority Review vouchers, a program offering an expedited drug review

As far as Eli Lilly's Dan Skovronsky is concerned, the revolving door with the FDA — often a subject of criticism — can spin in a direction that is beneficial for society.

A Lilly experimental weight loss pill showed superior blood sugar control in diabetic patients across two late-stage clinical trials

In a setback for Sarepta Therapeutics, a New York panel has voted unanimously to recommend the state Medicaid program pause coverage of a treatment for Duchenne muscular dystrophy.

And other pharma news from the Pharmalot campus thanks to the Pharmalittle newsletter.

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

In a first-in-the-nation move, a Colorado panel voted to limit what health plans in the state will pay for a costly arthritis treatment, a step that may encourage other states to follow suit.